Uma Sinha
Chief Tech/Sci/R&D Officer bij EIDOS THERAPEUTICS, INC.
Vermogen: 49 200 $ op 31-03-2024
Profiel
Momenteel bekleedt Uma Sinha de functie van Chief Scientific Officer van BridgeBio Pharma, Inc. en Chief Scientific Officer voor Eidos Therapeutics, Inc. (een dochteronderneming van BridgeBio Pharma, Inc.). Dr. Sinha was voorheen Chief Scientific Officer van Global Blood Therapeutics, Inc., Principal bij COR Therapeutics, Inc., Senior Director-Cardiovascular bij Millennium Pharmaceuticals, Inc., Principal bij Genencor International, Inc. en Vice President & Head-Biology bij Portola Pharmaceuticals, Inc. Zij is gepromoveerd aan de Universiteit van Georgia en heeft een bachelorgraad behaald aan het Presidency College.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
PROKIDNEY CORP. CLASS A
0.05% | 29-06-2023 | 30 000 ( 0.05% ) | 49 200 $ | 31-03-2024 |
Actieve functies van Uma Sinha
Bedrijven | Functie | Begin |
---|---|---|
EIDOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-06-2016 |
BRIDGEBIO PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01-04-2016 |
PROKIDNEY CORP. | Director/Board Member | - |
Eerdere bekende functies van Uma Sinha
Bedrijven | Functie | Einde |
---|---|---|
GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-06-2015 |
PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-12-2012 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | 01-01-2002 |
SOCL CAPI | Director/Board Member | - |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Corporate Officer/Principal | - |
Opleiding van Uma Sinha
University of Georgia | Doctorate Degree |
Presidency College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRIDGEBIO PHARMA, INC. | Health Technology |
PROKIDNEY CORP. | Health Technology |
Bedrijven in privébezit | 7 |
---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Social Capital Suvretta Holdings Corp. III
Social Capital Suvretta Holdings Corp. III Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. III is a blank check company, which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Henderson, NV. | Finance |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |